Sander Flaum urges Americans to ignore politicians’ calls to head north of the border for their prescription medication.
Even if drug manufacturers lower prices, it won’t fix the U.S healthcare system.
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Cutting prescription drug prices has become one of the most popular campaign promises of our time.
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
Why would any CEO tolerate a corporate culture that holds people back?